Payment overview · 2025
General Payments
$541.09
28 reported records · 15 companies
Healthcare provider profile · identity verified
Laina Feinstein, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHFIELD, MI · NPI 1467431031
Verified facts
What the public records show
CMS Open Payments records show Laina Feinstein, MD received $541.09 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.27 | 15.2% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $74.13 | 13.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.05 | 10.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $58.60 | 10.8% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $40.30 | 7.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.12 | 7.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.55 | 5.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.46 | 5.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.86 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.83 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.44 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.28 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.03 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.83 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.34 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $541.09 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $74.13 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.05 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.05 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $58.60 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $40.30 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 86 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 153 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 106 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 117 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 248 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
248 | 60 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
153 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
106 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 577 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 146 |
| Losartan Potassium | Losartan Potassium | 464 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 119 |
| Omeprazole | Omeprazole | 309 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 88 |
| Metformin Hcl | Metformin Hcl | 298 | 74 |
| Famotidine | Famotidine | 280 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 77 |
| Clonazepam | Clonazepam | 275 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 81 |
| Carvedilol | Carvedilol | 254 | 65 |
| Linzess | Linaclotide | 248 | 60 |
| Ranolazine Er | Ranolazine | 190 | 32 |
| Donepezil Hcl | Donepezil Hcl | 184 | 42 |
| Eliquis | Apixaban | 176 | 43 |
| Lisinopril | Lisinopril | 176 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 175 | 38 |
| Potassium Chloride | Potassium Chloride | 170 | 42 |
| Clonidine Hcl | Clonidine Hcl | 163 | 61 |
| Furosemide | Furosemide | 162 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 51 |
| Nifedipine Er | Nifedipine | 156 | 43 |
| Farxiga | Dapagliflozin Propanediol | 153 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 151 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 144 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 128 | 32 |
| Atenolol | Atenolol | 123 | 29 |
| Valsartan | Valsartan | 122 | 25 |
| Memantine Hcl | Memantine Hcl | 121 | 22 |
| Trazodone Hcl | Trazodone Hcl | 121 | 29 |
| Jardiance | Empagliflozin | 117 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 35 |
| Gabapentin | Gabapentin | 114 | 38 |
| Prednisone | Prednisone | 112 | 87 |
| Ipratropium Bromide | Ipratropium Bromide | 111 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 35 |
| Ezetimibe | Ezetimibe | 109 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 33 |
| Gemtesa | Vibegron | 106 | 32 |
| Montelukast Sodium | Montelukast Sodium | 106 | 34 |
| Lidocaine | Lidocaine | 103 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 26 |
| Azithromycin | Azithromycin | 93 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 30 |
| Mirtazapine | Mirtazapine | 92 | 22 |
| Nitroglycerin | Nitroglycerin | 88 | 39 |
| Creon | Lipase/Protease/Amylase | 86 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 38 |
| Tramadol Hcl | Tramadol Hcl | 84 | 31 |
| Cefdinir | Cefdinir | 83 | 64 |
| Glimepiride | Glimepiride | 82 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 32 |
| Memantine Hcl Er | Memantine Hcl | 77 | 16 |
| Allopurinol | Allopurinol | 75 | 16 |
| Finasteride | Finasteride | 75 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 74 | 30 |
| Ketoconazole | Ketoconazole | 74 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | 23 |
| Lorazepam | Lorazepam | 72 | 26 |
| Procto-Med Hc | Hydrocortisone | 72 | 23 |
| Mounjaro | Tirzepatide | 71 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 13 |
| Hydrocortisone | Hydrocortisone | 65 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 15 |
| Aripiprazole | Aripiprazole | 63 | 15 |
| Tradjenta | Linagliptin | 63 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 19 |
| Pregabalin | Pregabalin | 60 | 16 |
| Spironolactone | Spironolactone | 60 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 17 |
| Bumetanide | Bumetanide | 57 | 14 |
| Dutasteride | Dutasteride | 54 | 11 |
| Nystatin | Nystatin | 54 | 16 |
| Azelastine Hcl | Azelastine Hcl | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Entresto | Sacubitril/Valsartan | 51 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 50 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 50 | suppressed |
| Ozempic | Semaglutide | 50 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 49 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 24 |
| Ammonium Lactate | Ammonium Lactate | 47 | 16 |
| Olanzapine | Olanzapine | 47 | 12 |
| Repatha Syringe | Evolocumab | 46 | 16 |
| Sucralfate | Sucralfate | 46 | 13 |
| Midodrine Hcl | Midodrine Hcl | 45 | 12 |
| Simvastatin | Simvastatin | 45 | 13 |
| Vascepa | Icosapent Ethyl | 45 | suppressed |
| Fentanyl | Fentanyl | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 11 |
| Baclofen | Baclofen | 42 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 12 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Dexamethasone | Dexamethasone | 40 | 37 |
| Levofloxacin | Levofloxacin | 40 | 36 |
| Valacyclovir | Valacyclovir Hcl | 40 | 20 |
| Fluconazole | Fluconazole | 39 | 23 |
| Meloxicam | Meloxicam | 39 | 15 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 23 |
| Januvia | Sitagliptin Phosphate | 37 | 12 |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 13 |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | 14 |
| Telmisartan | Telmisartan | 36 | 13 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 25 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | 19 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Trulance | Plecanatide | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | 11 |
| Mupirocin | Mupirocin | 26 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 25 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Prolia | Denosumab | 20 | 12 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Nexium | Esomeprazole Magnesium | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Oxytrol | Oxybutynin | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Humira | Adalimumab | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mupirocin | Mupirocin Calcium | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Toprol Xl | Metoprolol Succinate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $541.09 · 28 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, CREON, EVENITY, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, LINZESS, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, ZENPEP, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error